All posts by Alzforum, Tom Fagan

AAN 2016: Rademakers and Traynor Share Potamkin Prize

At this year’s American Academy of Neurology annual meeting, held April 15 -21 in Vancouver, Canada, Rosa Rademakers and Bryan Traynor received the 2016 Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases. They share the $100,000 award for their studies on the genetics of neurodegenerative disease, most notably their independent discovery of a […]

Read more »


Top 10 AD News Trends 2013

Once again, before the world rings in the New Year is the time to let the major developments in the fields of Alzheimer’s and neurodegeneration pass before our collective mind’s eye. The year 2013 brought no breakthroughs, but many incremental steps did bring the fields closer to the goal of better diagnosis and treatment. Alzforum […]

Read more »


Does TauRx Drug Work by Oxidizing Tau?

21 February 2013. In 2008, Rember™, aka methylene blue, created a stir when the drug’s sponsors reported that it slowed cognitive decline in a Phase 2 trial for Alzheimer’s disease, while other scientists questioned that interpretation (see ARF related news story). The dye had been used for decades in various industrial, research, and therapeutic settings. […]

Read more »


Dementia Four Times More Likely in Pro Football Players

Players who spent at least five seasons battling it out in the National Football League (NFL) are three times more likely to die of a neurodegenerative disease than is the general population. Their risk for dying with dementia or amyotrophic lateral sclerosis hits fourfold. These sobering statistics appeared in the September 5 Neurology online. “Those […]

Read more »


AD-Springfield 2012: Stockholm: New Strategies for Immunotherapy

Immunotherapy continues to be a major therapeutic strategy for Alzheimer’s disease, and more recently for other neurodegenerative diseases as well. At the 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, researchers discussed some new immune-based approaches for therapy, including those capitalizing on the body’s own antibodies for passive immunotherapy and novel antigens for active […]

Read more »


Fluorescence—Not Just for Protein Anymore, Now RNA, Too

Move over, green and related fluorescent proteins. As reported in today’s issue of Science, at least one lab bench is aglow with fluorescent RNAs. Researchers led by Samie Jaffrey at Cornell University, Ithaca, New York, developed a range of RNA molecules, or aptamers, that tightly bind fluorescent compounds similar to that in green fluorescent protein […]

Read more »


Uppsala: Immunotherapy—Not Just for AD Anymore

See Part 1 and Part 2. Read the entire series. 9 July 2011. As immune-based therapies targeting Aβ and tau are beginning to show promise for the treatment of Alzheimer’s, what about other disorders of the nervous system? At the 2nd International Conference on Neurodegenerative Disorders: Immunotherapy and Biomarkers, which took place 26-27 May 2011 […]

Read more »